Bayer AG’s Phase III failure

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Bayer’s Phase III failure; US group seeks Japan changes; AstraZeneca winning AKT race for now; NASH developments at AASLD; and the Q3 impact of China’s corruption campaig ...  Afficher plus

Matthew Wood, director and chief scientific officer at Oxford-Harrington Rare Disease Center, discusses the state of rare disease R&D, the evolving landscape of genomics and genetic therapies, and the challenges around the biopharma industry’s narrow focus on only 5-10% of rare d ...  Afficher plus

As the global push for Environmental, Social, and Governance (ESG) practices and sustainability gains momentum, CFOs face the challenge of translating complex mandates into actionable strategies that simultaneously satisfy regulators, investors, and the company's bottom line.< ...

As the global push for ESG and sustainability gains momentum, CFOs find themselves translating complex mandates into actionable strategies that satisfy regulators, investors, and the bottom line alike.

This week: The first in a new state-of-sustainability series, Brendan May, business expert and founder of Robertsbridge, talks with Innovation Forum’s Ian Welsh about the apparent current crossroads for sustainable business and why some companies are ...

We've all got a lot savvier about sustainability in recent years. We know the size of the climate challenge facing the planet. And we know that the planet needs more than statements, green logos and commitments to use the printer less to tackle it. As we all make more sustainable ...  Afficher plus